Alimera

Less than one hour before the close yesterday, Benzinga heard positive rumors that the NDA for ILUVIEN, which was resubmitted roughly two weeks ago, had been accepted by the Food and Drug Administration. The drug, which is a joint venture between pSivida (NASDAQ: PSDV) and Alimera Sciences (...